ImmuPharma : Phase 2/3 adaptive clinical trial of P140 (Lupuzor™) in Lupus to commence following FDA meeting

Phase 2/3 adaptive clinical trial of P140 in Lupus to commence following FDA meeting

19th June 2023 - 9:43 am

ImmuPharma PLC , the specialist drug discovery and development... | June 19, 2023

Related Keywords

Tim Mccarthy ,Avion Pharmaceuticals ,Drug Administration ,Licence Agreement ,Art Deas ,